<DOC>
	<DOCNO>NCT01045109</DOCNO>
	<brief_summary>This clinical trial aim measure effect vitamin D3 supplementation serum prostate-specific antigen ( PSA ) level patient diagnose early stage , low-grade , low-risk prostate cancer ( Gleason score less than/equal 6 ; PSA le than/equal 10 ; clinical stage T1C T2a ) , elect disease monitor active surveillance least one year .</brief_summary>
	<brief_title>Vitamin D3 Supplementation Participants Diagnosed With Early-Stage Prostate Cancer Who Decide Undergo Active Surveillance Treatment Regimen .</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>lowgrade prostate cancer serum PSA le than/equal 10 ng/ml Gleason score less than/equal 6 refer treat physician treatment plan active surveillance one year serum creatinine less than/equal 2.0 mg/dL serum phosphate ( measure phosphorus ) great 2.3 less 4.8 mg/dL serum calcium great 8.5 less 10.5 mg/dL concurrent malignancy , except nonmelanoma skin cancer history sarcoidosis history high dose ( great 1,000 IU daily ) vitamin D3 supplementation history hypercalcemia treatment lithium medication</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>vitamin D3</keyword>
	<keyword>early stage</keyword>
	<keyword>active surveillance</keyword>
</DOC>